Drug Product Registration Processes
|
|
- Aron Hunter
- 7 years ago
- Views:
Transcription
1 Drug Product Registration Processes Joel Finkle CSC CSC Grants March 2013 ABSTRACT Regulations in the US and Europe require technologies for registration of medicinal products in a structured format to facilitate inspections, safety tracking and licensing. The US Food and Drug Administration (FDA) system is based on a technology called Structured Product Labeling and is used in Drug Registration and Establishment Listings (DLER). The European Medicines Agency (EMA) has built a system primarily for pharmacovigilance, called Extended EudraVigilance Medicinal Product Dictionary (XEVMPD), which was instituted in 2012 based on an earlier, simpler format. Both of these provide a bridge to a 2012 ISO standard called Identification of Medicinal Products, or IDMP, which is expected to go into production use in 2015 or While there are features in common to all three, there will be a significant effort required to provide a system that can migrate the required data to the international standard. All biopharmaceutical companies will need to update the existing databases to the new standard. For the current standards, companies have been driven to create one-off registration documents in the specific formats, requiring long-term relationships with vendors familiar with the standards. However, that process does not build the knowledge base within the company. This paper addresses the requirements of the two current and one future standard, as well as the processes used by pharmaceutical companies to maintain such information, and suggests best practices for maintenance of such databases within a company. A key outcome is a solution architecture and set of processes for knowledge structures that would permit creation of SPL/DLER, XEVMPD and IDMP product registrations from a common set of data. This impacts a variety of roles throughout a company including obtaining, verifying and maintaining data. LEADING EDGE FORUM CSC GRANTS Copyright 2013 Computer Sciences Corporation. All rights reserved.
2 TABLE OF CONTENTS 1 BACKGROUND Business Case for Drug Product Registration Product Terminology Regulation and Implementation CSC Current Offerings DATA FORMATS FOR DRUG REGISTRATION SPL Data Listings and Establishment Registration (DLER) Extended Eudravigilance Medicinal Product Dictionary Identification of Medicinal Products (IDMP) Commonalities and Differences CHALLENGES FOR IDMP IMPLEMENTATION Substance Registration Data Ownership Data Maintenance DRUG SPONSOR COMPANY PROCESSES Regulations Data Maintenance Processes Message Authoring Registration Process DRUG SPONSOR REQUIREMENTS Consulting and Other Strategic Services Conversion and Authoring Services and Tools TRS Tracker and other Total Regulatory Solution software CONCLUSIONS BIBLIOGRAPHY LIST OF FIGURES Figure 1 IDMP Data Model Figure 2 Comparison of IDMP with DLER and XEVMPD ii
3 LIST OF APPENDICES APPENDIX A : COMPARISON OF DATA ELEMENTS Appendix A-1 : Medicinal Product (ISO 11615) Appendix A-2 : Pharmaceutical Product ID (ISO 11616) Appendix A-3 : Structured Substance (ISO 11238) APPENDIX B : ENTITY RELATIONSHIP MODELS Appendix B-1 : TRS Tracker Data Model Appendix B-2 : IDMP Data Model iii
4 1 BACKGROUND 1.1 Business Case for Drug Product Registration Current regulations in the US and Europe require substantially different technologies, terminologies and vocabularies for registration of medicinal products that are approved for use in human medical treatment, or for clinical trials. Registration of medicinal products is part of the licensing process, and is a paper activity in most countries. Europe and the US are ahead of the game by having electronic file formats specific to the drug product registration. By providing an electronic medical products dictionary, the regulatory agencies are able to swiftly follow up on cases of counterfeiting, illegal import, contamination, patient safety, and supply shortages, as well as maintain the inspection audits of establishments involved in the manufacture, quality testing, packaging, import and distribution of medicines. It is also worth noting that one of the major industry is for monitoring of drugs across classes and geographies rather than as discrete marketed products. This means that not only do market authorisation holders have to provide internally consistent data but also they need to provide data that can be sensibly aggregated with data from other companies for other products in other markets TECHNICAL CONSIDERATIONS It is important to note that the message formats used by the electronic standards are designed for consumption by an agency, and do not necessarily reflect the processes used by pharmaceutical companies for maintaining that information. In the US, the FDA requires a Drug Registration and an Establishment Listing, both of which are based on the HL7-developed standard Structured Product Labeling (SPL). These describe the product, and the facilities in which it is manufactured, imported, and otherwise processed. In Europe, the EMA initiated a new standard in 2011 called Extended Eudravigilance Medicinal Product Dictionary (XEVMPD), with a requirement that all marketed products be registered with the agency by July 2012 for the purposes of rapid access to a database of products in the case of safety issues. The two systems have many features in common, and a number of items that are unique to each INTERNATIONAL APPROACH A third system, IDMP (IDentification of Medicinal Products) was approved in November of 2012 as an ISO standard (actually five standards, see below). IDMP was developed as an outgrowth of the Common Product Model (CPM) at HL7, so it has many features in common with SPL. The European XEVMPD standard has been stated as having a sunset date of when IDMP becomes implemented. This is estimated at 2015 or more likely All biopharmaceutical companies will need to update existing databases to the new standard. If previous regulatory agency behavior is followed, a short (less than one year) period to adapt to the new standards will be granted for all companies to register all existing products. For previous standards initiatives, companies have been driven to create one-off registration documents in the specific formats (SPL and XEVMPD), often requiring long-term relationships with vendors familiar with the standards, but this does not build the knowledge base within the company. Development of a process for maintaining and messaging the information would improve the value of the information within customers enterprise knowledge warehouses, and improve their bottom line through the use of fewer contracted services to create and maintain such registration data. 1
5 Among the cases used to justify the system that will improve patient health and safety include: Tracking abused drugs Realization of the level of Oxycontin abuse led to changes in its formulation to make it less appealing when a crushed tablet is inhaled. Product Labeling and Packaging the accidental overdose of heparin in actor Dennis Quaid s children has led to changes in how products are packaged and labeled (different dosage strengths now have different color labels on the bottles) Avoidance and mitigation of drug shortages (e.g. temporary importation from another country of the same product with a different approval number) Tracking drugs used in clinical trials may permit mining trial data for new uses (such as previous side effect), and tie efficacy and safety to genotypes Tracking generic drug usage, since generic drugs are now 80% of medicines used (but only 20% of the dollars spent), but having the same name with different manufacturers makes it difficult to gather the sum of any substance s usage. 1.2 Product Terminology The data standards used for drug product registration include a number of similar terms which can be difficult to distinguish. They build on top of one another, and occasionally loop back into recursive structures. The key thing to understand is the set of layers of the product definition. The product registration systems at various agencies are concerned with tracking a product for such reasons as ensuring supply, ensuring that supply is genuine and uncontaminated, and tracking any issues with using that product. For that reason, it is necessary to distinguish between what is administered to a patient, as a different thing from what is sold by the sponsor, but both have their own means of unique identification. MEDICINAL PRODUCT: This is a product administered to humans (or animals) for treating, preventing, diagnosing disease or restoring, correcting or modifying physiological function. The Medicinal Product is the form of a dose of the product as sold. It may have multiple components or manufactured items and one or more pharmaceutical products. Invalid source specified. MANUFACTURED ITEM: This is the description of a product contained in the packaging of the Medicinal Product. Invalid source specified.. The manufactured items may include administration devices such as syringes. PHARMACEUTICAL PRODUCT: This is the version of the product as administered. The ISO standards described below define this as qualitative and quantitative composition of a Medicinal Product in the dose form approved for administration in line with the regulated product information. Invalid source specified.. In many cases, this may be the same as the Medicinal Product (e.g. a tablet), in others (e.g. a powder and solution which must be combined), a process is needed before it can be administered. In a small number of cases, there may be multiple pharmaceutical products in a medicinal product package: an antibiotic tablet packaged with a topical cream is two pharmaceutical products. PACKAGED MEDICINAL PRODUCT: This is the product as sold in its outermost container, e.g. a bottle of tablets, or a carton containing vials. The packaging is typically marked with an identifier of what batch it came from, to assist in tracking quality or safety issues in the product. PACKAGE ITEM: A Packaged Medicinal Product may contain multiple package items, such as vials or blister packs, which have their own containers. This may have several nested layers (e.g., a vial in a pouch in a carton). At the bottom level, these will contain Manufactured Items. 1.3 Regulation and Implementation Currently, only the US and the European Union members of the European Medicines Agency have a standard electronic data format for drug listings. These formats are rather different from each other, 2
6 partly due to differences in how the data is used, and the timing of the standards: the US has a focus on inspection of manufacturing and processing facilitiesinvalid source specified.), the EMA format was designed as a stopgap until the IDMP standard became available. The Identification of Medicinal Product (IDMP) standard will be adopted by all three regions participating in the International Conference on Harmonisation (ICH) adding Japan to the above US and EU countries. In addition, because it is an ISO standard, other jurisdiction are more likely to adopt an existing standard than design one from scratch. Countries that have followed ICH guidance for other electronic standards include Canada, Switzerland, and Australia for marketing applications, with influence also seen on the standards used in Russia, China, Southeast Asia (ASEAN countries), South America and the Gulf Cooperation Council. The ISO ICSR standard which is being implemented through ICH group E2B is will be used in Australia as well as the ICH partner nations. It is expected that the US and EU will move to the IDMP standard within about two years after the development of implementation guides. Since the ICH guidance is expected in March of 2013, with regional guidance following shortly after, this should be in 2015 or It is unknown at what speed sponsors will be required to meet the new standard, but past experience has shown that agencies may be insensitive to the costs of rapidly implementing a new standard: The initial implementation of SPL for the Content of Labeling in 2005, and the update to the Physician s Labeling Rule format in 2006 provided less than a year between distribution of the final guidance and required use. Similarly, the XEVMPD standard in the EU was announced in September 2011 for implementation by July of 2012, but the final version of the standard was not made available until March of 2012 a mere four months prior to the deadline. The short timeframes between final issuance of guidance and the requirement to comply mean that service and software companies will need to prepare services, software and related training and implementation services prior to the final guidance and implementation guides, with anticipation of last-minute changes to those products. 1.4 CSC Current Offerings The Life Sciences groups within CSC offers the following services and software related to drug registration dictionaries: SPL Conversion Services The Regulatory Services group provides translation from Word and other formats into SPL for Content of Labeling and DLER. Regulatory Information Management Consulting the author has been assigned to contracts involved in implementing Regulatory Information Management systems for clients. Other consultants have been involved in implementation of TRS Tracker, XEVMPD implementation, and data gathering in Europe. TRS Tracker Software and Implementation Version 5.2 of TRS Tracker can produce reports on the Drug Product Tracking database that can be used to create XEVMPD records in the EVWEB system at EMA (see below), and create XEVMPD records directly TRS Tracker can also be extended in the future to deliver IDMP messages, and with small changes could be delivering SPL DLER today (although content of labeling would be a significantly different effort). 3
7 2 DATA FORMATS FOR DRUG REGISTRATION The following sections detail the data formats of the three registration standards, and how their concepts build on each other. While the level of detail is daunting, the introductions and summaries of each section are valuable for understanding the implementation requirements, and the scope of work that medicinal product manufacturers will need to go through to implement these requirements. 2.1 SPL Data Listings and Establishment Registration (DLER) The Structured Product Labeling format was developed in 2004 by Health Level 7 (HL7) for FDA s use, initially for the content and format of labeling. Release 3 was the first version required for use by the public, and Release 4 (SPL R4) was developed specifically to send structured data for Drug Listings and Establishment Registrations (DLER)Invalid source specified.. Per Section 510 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), it is required for firms that manufacture, prepare, propagate, compound, or process drugs in the U.S. or that are offered for import into the U.S. to register with the FDA. These domestic or foreign firms must at the time of registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution in the U.S. Foreign establishments must identify a U.S. agent at the time of their registration. Invalid source specified.. The Drug Listing file is designed to replace the previous paper FDA forms 2657 and 2658, and includes the following information from those forms: Name of establishment(s) manufacturing or processing the listed drug and the type of operation(s) performed; DEA schedule; Route(s) of administration; Inactive ingredients; Marketing information (e.g., category, start/stop date); Information related to the application (e.g., type and year of approval) or OTC monograph citation number; Package size and type. In addition to the information required on the older paper forms, the Drug Listing SPL file also includes: NDC Product Code for the Source Drug Repacked or Relabeled Unique Ingredient Identifiers (UNII) Data Universal Numbering System (DUNS ) Number for establishments and sponsor Confidentiality Flag Distinctive Characteristics (flavor, color and an image of solid dosage forms) The Drug Listing and Establishment Registration may be created using the FDA-supplied E-Submitter tool, or delivered directly through the Electronic Submission gateway. Although the SPL format is also used for the Content of Labeling, the Drug Listing and Establishment Registration does not include the sections that include the narrative labeling document. One of the criticisms of the SPL format is that it has a lot of complexity, but each document type uses only a portion of that total complexity. While that makes each document type manageable, it makes using standard XML technologies such as Microsoft Office tools extremely difficult, as the applications can not differentiate between the document types. Approximately 8000 compounds in 50,000 unique packages are registered in SPL.Invalid source specified. FDA has recently encouraged updating all SPL files to Release 4, and in the past year 4
8 has managed to reduce this from 1600 separate labels in the old format to a mere 11 on eight compounds. The most recent version of the SPL standard, Release 5, also includes structures for Device Listings. Compared to the product models in section 1.2, it s not as complete: The Pharmaceutical Product concept is not included as a separate concept, and there is no detail on package items or manufactured items that are subsets of the whole. 2.2 Extended Eudravigilance Medicinal Product Dictionary The XEVMPD message format is called Extended Eudravigilance Product Report Message (XEVPRM). The format s initial specifications as part of EMA Article 57, issued in September of 2011, were extensive. With a requirement to implement by July 2012, many pharmaceutical companies complained that the requirements were beyond reasonable costs of implementation, especially the information required for the structured substance information (SSI), which specified detailed information about active and inactive substances in each product. Coupled with this was the problem that many of the controlled vocabularies, and details on implementation of parts of the standard, had not yet been provided. This would have greatly increased the risk that sponsor organizations would not be able to comply. EMA, however, was limited by European Union legislation, and could not delay implementation of the Eudravigilance medicinal product dictionary. The only options available were to (a) reduce the requirements to a minimum, and (b) have a flexible attitude to enforcement of compliance. The latter is significant because EMA could have removed products from the marketplace from sponsors that had not filed the XEVPRM data by July 2, 2012, but did not. Updated specifications were issued in March of 2012Invalid source specified. just four months prior to the deadline for submission. These updated specifications were based mainly around a subset of the requirements of the EMA Summary of Product Characteristics (SmPC)Invalid source specified.. It should be noted that the SmPC includes preclinical safety data, shelf life and Contraindications, none of which are required by XEVMPD. Each approved or investigational (development) product must be submitted to each country where it is marketed, in every official language of that country. The XEVPRM standard is designed as a single message (plus an acknowledgement message format from the agency) that indicates items to be registered, or changes to existing registered items. The types of items that can be registered or changed include: Approved or Development Products Approved or Development Substances Organisations (e.g. Sponsors, Regulatory Authorities) Attachment Files Master File Locations Sources for information references Updates to controlled vocabularies: ATC Codes, Pharmaceutical Dose Forms, and Administration Routes Each new item registered is sent with a local key, and the acknowledgement message will assign an official EV Code which is to be used for all future references to that item. Some items such as Attachments are meant to only be submitted, never modified instead, a new file is submitted with its own code if an attachment such as labeling or the SmPC document is sent. The use of EV Codes enables references to substances. In other words, for the item types listed above, other parts of the XEVPRM message can just use the code, and not completely specify the entire set of data each time 5
9 and place where it is used. a Each place where EV Codes are used also requires indicating whether it is a local or EV-issued (called the Resolution Mode), and previous codes used by the same item. Development and Approved Substances in EVPRM specify the following items: A valid reference source for the substance name The English name of the substance The Chemical Abstracts Service (CAS) Number (optional) The molecular formula (optional) The class of the substance (e.g. chemical, protein, etc.) (optional) The Chemical Biological Description (CBD) (optional) Translations and Aliases of the substance name International Codes used to identify the substance Attachments such as the Printed Substance Information Structured Substance Information (optional) Development and Approved Products in EVPRM specify the following items: Sponsor or Market Authorisation Holder information Reference to the Qualified Person for Pharmacovigilance (QPPV) location Contact Information Market Authorisation, which consists of Country Procedure Status Number Authorisation and Withdrawal Dates MRP Number EU Number Orphan Drug Status Intensive Monitoring Status Presentation Name References to ATC Codes Indications Attachments Pharmaceutical Product information, consisting of Reference to the Pharmaceutical Form Codes Administration Routes Active Ingredients Excipients (optional) Adjuvants (optional) Medical Devices (optional and rare, such as cell scaffolding) The EVPRM model aligns closely with the product model in section 1.2. It includes the Pharmaceutical Product and Medicinal Product concepts, although its packaging information is scant. a It is unfortunate that the same approach was not also applied to the XEVMPD documentation, as repeated sections such as references are described in identical detail every place they are used, increasing the size and tedium of the specification documentation. 6
10 As of September of 2012, EMA had received 229,401 XEVPRM messages, but had not yet acknowledged 20% of the total messages. This covered 236,827 products much less than the 450,000 expected. Some of this is based on backlog of registration of applicants. The EVPRM messages are sent to EMA by one of two methods: if the Market Authorisation Holder/Sponsor has capabilities to create the XML, files may be submitted via the EMA Gateway. This provides for greater efficiency, but requires more technical expertise on the part of the drug s owner. Otherwise, the EVPRM messages may be created and eventually maintained through the EVWEB interface, a web-based application that permits entry of all information in the EVPRM data structure. This can be tedious for creating multiple records but requires little technical expertise. EMA offers an online course for using EVWEB as a series of videos on YouTube, and in fact requires the course to be taken before certifying staff for use of the system.invalid source specified. An area which has made penetration of the service market for EVPRM difficult is that software and service vendors are not granted access to the production or test EVWEB or Gateway systems except on behalf of a market authorisation holder. As of the most recent Article 57 EMA meeting, EMA has stated that they will reconsider this position. One of the challenges of the XEVMPD system is that EMA has spent a lot of time and effort getting compliance with the initial submission, but as of this writing has not yet completed guidance on updates to drug product information. For instance, they have stated that most updates should be done within 30 days of a change to the approved product (close of the procedure). However, they have not stated if it is necessary to send all changes or only those that require prior approval or waiting period processes, or also those that use the do and tell process. Those changes that are ordinarily immediately implemented and communicated to the agency within twelve months may end up requiring a more-immediate XEVMPD submission.invalid source specified. Formal guidance on maintenance of data is not expected until March or April of Identification of Medicinal Products (IDMP) The IDMP standard began in 2003, with a primary goal to align it as a set of identifiers for use with the ICSR (Individual Case Safety Report) standard for safety reporting. It was approved as a set of ISO standards in November of 2012: ISO 11238:2012: Health informatics Identification of medicinal products Data elements and structures for the unique identification and exchange of regulated information on substances Invalid source specified. ISO 11239:2012: Health informatics Identification of medicinal products Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaginginvalid source specified. ISO : Health informatics Identification of medicinal products Data elements and structures for the unique identification and exchange of units of measurement Invalid source specified. ISO 11615:2012: Health informatics Identification of medicinal products Data elements and structures for the unique identification and exchange of regulated medicinal product informationinvalid source specified. ISO 11616:2012: Health informatics Identification of medicinal products Data elements and structures for unique identification and exchange of regulated pharmaceutical product information Invalid source specified. For the sake of brevity, these will be referred to throughout this document without the 2012 suffix, which only indicates the year of approval. 7
11 The standards were developed as an expansion of the Common Product Model at Health Level Seven (HL7). This builds on the technology and experience of the SPL standard, and the Common Product Model is used at the heart of many health standards to describe medicinal products. The five standards build from basic concepts up through the full Medicinal Product definition. ISO is essential for understanding the concepts of dosage forms, units of presentation, routes of administration, and packaging, which are used in the ISO standard. ISO specifies the methods of communicating units of measurement, used across the rest of the standards in the set. ISO is a detailed definition of how to describe a substance (active or inactive) that is used in making up a medicinal product, from its chemical structure to its methods of manufacture, and is referenced in ISO and ISO is relatively brief: it covers only a set of identifiers used to describe the pharmaceutical product, which is the administrable form of the medicinal product. Lastly, ISO is the over-arching specification for the medicinal product, which references all of the other standards. The primary purpose of IDMP is to create the authoritative identifiers for a medicinal product within a given regulatory authority s jurisdiction. The specific case it was created for is the ICSR standard created by HL7, approved as ISO :2011Invalid source specified. and implemented by ICHInvalid source specified.. By having a definitive identifier for a packaged product within each participating country, it should be possible to trace patterns in adverse drug experiences and gather statistics on where labeling should be changed, or products withdrawn. Because ICSR was approved before IDMP was completed, ICSR was implemented without requiring an IDMP identifier in their messages. After IDMP is implemented, ICSR will likely change to mandate the use of the Medicinal Product Identifier (MPID see below).invalid source specified UNITS OF MEASUREMENT (ISO 11240) ISO builds on the earlier ISO Guide 99:2007, which describes the SI (International System) of units, and creates data structures for communicating values and units for electronic messaging.invalid source specified. Distinct in the ISO methodology is splitting the unit type (e.g. grams ) from the scale (e.g. milli ), so instead of just measuring in mg, the standard specifies M and G as separate terms. There are three additional concepts crucial to measurements for medicinal products: 1. Ratios of measurements. This is typically in the form of a numerator quantity per denominator units, e.g. 5 mg/ml, which should technically be 5 mg per 1 ml. 2. Units of Presentation. For many dosage forms, the form itself is a single object, which means that the strength of a product might be expressed as per tablet or per spray. This is the presentation unit, and is an used instead of the denominator unit mentioned above. 3. Reference measurements. Some products are formulated as, for instance, a salt of a drug substance. In cases such as this, the measurement may be expressed both as the absolute (e.g. 300mg of Lithium carbonate), and its reference substance (12.2 mmol lithium). There are other reference measurements such as a particular measurement procedure. These concepts are critical underpinnings of the Substance (11238) and Medicinal Product (11615) portions of the standard. The EVMPD uses a very similar data structure for measurements, but does not include the reference measurements as part of the standard data structure. The SPL R4 Drug Listings do not use the above means of specifying units or reference measurements ADMINISTRATION AND DOSAGE FORM TERMINOLOGY (ISO 11239) The Product definitions describe the packaged and consumed items, but additional information is needed to describe how a product is prepared for use, and how it is actually used. This is as simple 8
12 as a tablet, or as complicated as a powder and solution which must be combined, placed in a syringe, and then injected in a particular location. The primary dose form information is a coded value, which will be supplied as a controlled vocabulary as part of the ICH Implementation Guide. The dictionary for dose forms is defined in ISO to further classify each value with a Basic Dose Form (e.g. Tablet versus Extended Release Tablet ), Release Characteristics (the Extended Release portion), Transformation (e.g. dissolution of the powder in a solvent for a Powder and Solvent for Injection ), Intended Site (e.g. intramuscular for an injection dose form), and Administration Method (e.g. injection ). Not all dose forms will use all five modifiers. Because existing standards of SPL and XEVMPD have different dictionaries for dosage form and administration method, these modifiers will assist in mapping one IDMP to many XEVMPD or SPL forms, or one SPL or XEVMPD to many IDMP forms. In addition, there are combined dose forms, where multiple dose forms listed above are transformed into a single administrable form For example, a powder may be packaged with a vial of solvent, to be combined as a powder and solvent for solution for injection. It also defines the structures for the packaging class, which includes a container, its closure, and administration devices. At a minimum, there is a Packaging Category (a coded value), but it can be subdefined by one or more of the closure ( screw-cap, stopper ), container ( box, ampoule ) and administration device ( needle, oral syringe ) categories. ISO also defines the controlled vocabulary that will be created for units of presentation, and the Route of Administration controlled vocabulary structure. Invalid source specified SUBSTANCE DEFINITION (ISO 11238) Unique in the ISO IDMP standards, does not have an approved message format that is already in use: There is no existing standard for substance specification. The XEVPRM format originally included one, but it was made optional: not only was it removed from the most recent guidance, to this author s knowledge, it has not been implemented by drug sponsors. The US drug listing sections require nothing more than the identification of the substances, not a description of them, using the Unique Ingredient Identifier (UNII). In the US, the existing Substance Registration System consists of data entered by National Library of Medicine staff, based on drug submissions it s a system designed for use by experts to exactly match their specificationsinvalid source specified., which can then be downloaded from the NLM website.invalid source specified. From this system are issued the Unique Ingredient Identifiers. It is anticipated that the NLM system will become the basis for the international Substance Registration System used by IDMP, with the difference that the data will be supplied by the drug sponsor. It is not clear who is responsible for substances off patent or for common, inactive substances (water, corn starch and silicon dioxide, for instance). The current systems at the US National Library of Medicine used for maintaining the UNII identifiers are proprietary, and would do not provide information in publicly available formats. The UNII provides a unique, easy to validate identifier, and is likely to remain the ISO identifier b although its name may change. A key benefit of the centralization of substance IDs will be that companies will have an alternative to the expensive commercial registration of a CAS Number. Currently, countries may maintain their own substance systems. Germany has a system with 41,000 unique substances and 182,000 names. The US system is of a similar size (50,000 compounds), but not all items are the same, due to the substances which are regulated, and local pharmacopeias. b It is interesting to note that Wikipedia has chosen the UNII for tagging medicinal substances. 9
13 ISO specifies the following information be provided for each active or inactive substance. Invalid source specified. For all substances A Substance ID will always be listed. Without an implementation guide, it is unknown how new substances will get identified. It is likely a mechanism similar to the EVMPD local key will be used. Some substances may be subclassed into Specified Substances, indicating substances not easily otherwise defined, or specific versions of a substanceinvalid source specified.. Specified substances may be specific to a regional authority, such as a country s pharmacopaeia s registry. Note that Specified Substances are not yet part of the US SRS. Group-1: Multiple-substance materials, such as allergenic and herbal extracts Group-2: Manufacturer and minimal manufacturing information Group-3: Graded materials (US Pharmacopeia, European Pharmacopeia, technical, standardized substances) Group-4: Detailed manufacturing information If a substance is described as a Specified Substance, it will have a Parent Substance ID Group 4 can have a parent of any of the others including a non-specified substance, Groups 2 and 3 can have a parent of Group 1 or a non-specified substance, and Group 1 s parent would only be a non-specified substance. In some cases, the use of a specific specified substance is critical: The source of a starch, for instance corn versus potato, could affect the allergenicity of a product. Product manufacturers should be encouraged to use as specific a substance as possible. Detailed Name information is provided, including the official names specific to each jurisdiction (in other words translations), and reference sources for each name (e.g. US Pharmacopaeia) Structure information, including optical activity, molecular formula, attachments further describing the structure, and isotope information for radiolabeled compounds indicating what atoms are substituted with which nuclides. Where needed, Modification information, which describes how a substance is changed from a basic form. This can include any number of modifications, which may be physical, structural, or agent modification. Where needed, Reference information which includes classification of the substance, gene or gene elements that are the source of the material, and the target gene to be affected, and relationships with other substances. Each of these items may have a reference source. Source Materials, optionally indicating the organism (and specific parts or fractions) from which the material is obtained For Chemical Substances Stoichiometric Information Comments Properties (type, name, ID, reference substance name and amount) Moieties (Role, ID, Name, and Amount) Reference Sources For Protein Substances Protein Sequence Type Subunits (sequence, length, terminal modifications) Comments Disulfide Linkages 10
14 Modifications, if any Molecular weight (may be multiple if different methods are used) Properties Glycosylations (of N, O and C type) Reference Sources For Nucleic Acid Substances (DNA, RNA) Nucleic Acid Sequence Type Subunits (sequence, length, terminal modifications) Comments Molecular weight (again, may have multiple if different methods are used) Modifications, if any Properties Reference Sources Polymer Substances Polymer Class (e.g. homopolymer, copolymer) Polymer Geometry (e.g. linear, branched, network) Sequence type (random, block, alternating) Comments Monomers (ID, name, amount) Structural Repeats (orientation of polymerization, degree of polymerization) Molecular Weights Source Materials, optionally Modifications, if any Reference Sources Properties Structurally Diverse Substances (e.g. extracts from biological sources that cannot be enumerated, such as orange oil, cells and tissues) Comments Molecular Weights Source Materials Modifications, if any Glycosylations Properties Reference Sources Mixture Substances These are essentially just lists of other substances Two or more Constituents (ID, Name, Requirement) Mixture Type Source Materials Modifications Specified Substances Group 1 Constituents (Substance ID, Name, Role, Amount) Properties Physical Form (State, Form-Type, Amount) Reference Sources Specified Substances Group 2 Parent Substance 11
15 Manufacturing (Manufacturer ID and Name, Type, Production Method and System, Critical Process Version Number, Reference Sources) Specified Substances Group 3 Parent Substance Grade (Type, Name, Reference Source) Specified Substances Group 4 Parent Substances Grade (Type, Name, Reference Source) Analytical Data (Specifications, jurisdictions for a specification, analytical method, values, reference sources) Constituents (Substance ID, Name, Role, Amount) Properties Physical Forms (State, Form-type, Amount) Manufacturing (more detailed than Group 3, includes resultant materials, processing materials, starting materials, processing equipment) Reference Sources How that substance is used is specified in the product: for example, Dextrose may be an inactive ingredient in a tablet, but the active substance in intravenous nutrition PHARMACEUTICAL PRODUCT ID SETS (ISO 11616) ISO is relatively brief, defining a sub-structure that is part of the ISO Medicinal Product. It weaves the concepts of the substances and specified substances of plus the dosage forms of and the units of measurement and reference strength of This set of identifiers is used to describe the administrable product form, after any reconstitution or transformation of the Medicinal Product. A single Pharmaceutical Product ID Set (PhPID Set) will be described in terms of a set of active ingredients: either substances or specified substances, with an optional device (e.g. a cell substrate framework), and sub-ids for the product with strength and unit of presentation, the administrable dose form, and both the dose form and strength. Each of the sub-ids includes a set of substances, each with a role (active, inactive, adjuvant), and a reference strength. The PhPIDs are generic for a given clinically equivalent product: product alone, product and dosage form; product and strength; and product, dosage form and strength. This enables tracking safety issues for, for instance, 325 mg aspirin tablets, aspirin of unknown dose, or aspirin of 325 mg of unknown dosage form, etc., all regardless of brand.invalid source specified. It would be expected that all aspirin tablets would include two common PhPID in their sets (aspirin, aspirin tablet); all 325 mg dosage forms would have two common IDs (aspirin, aspirin 325 mg regardless of whether it s a tablet, a capsule, or a gelcap) and so on. A similar concept exists in previous standards: The SNOMED Clinical Terms document includes a Non-Proprietary Medicinal Preparation Invalid source specified., and The US National Library of Medicine s RxNorm has the concepts of Semantic Clinical Drug (SCD), Semantic Clinical Drug Form and Semantic Clinical Drug Component.Invalid source specified. It is still not clear why each of these PhPIDs must carry their own sets of ingredients it would be just as effective to reference a common set of ingredients for the common Pharmaceutical Product MEDICINAL PRODUCT DEFINITION (ISO 11615) The overall medicinal product in ISO combines all the concepts of the other four standards documents. Corresponding to the product model concepts presented in section 1.2, an approved 12
16 medicinal product (or investigational product approved for clinical trials) would be assigned a Medicinal Product Identifier (MPID) or Investigational Medicinal Product Identifier (IMPID) c. Each packaging type (e.g. a 20-capsule bottle versus a 50-capsule bottle) would receive a unique (Investigational) Medical Product Package Identifier PCID (or IPICID). Each batch of the outermost packaging, and each batch of any intermediate packaging would receive Medicinal Product Batch Identifiers (BAID_1 and BAID_2 respectively, with IBAID_1 and IBAID_2 for investigational batches). From any of those identifiers, the product can be immediately traced to determine its name, its marketing status, which Regulatory Authority authorized it, its composition (manufacturing, ingredients, dosage form, etc.), adverse experiences and Contraindications, and other documentation.invalid source specified. Currently, only biological products marketed in the US have batch IDs submitted to the FDA. It is unclear whether this would be expanded beyond biologicals. The product information is organized hierarchically in two ways: For packaged items, the data is organized from the outermost to innermost contents, down to their ingredients. For the pharmaceutical product that is actually consumed, data is organized from the administrable form down to the items that make up that form those will be the same items as those specified in packages, although no linkage is provided between the two sets of of structures.. For the identification of a medicinal product, a change to any of the following items would constitute a different identifier: Product Name, Brand and Description Formulation (active ingredients) Strength Dosage or Usage Net Quantity (weight, volume or other dimension in a package) Packaging Configuration, including sub-packaginginvalid source specified. The MPID must indicate the ISO country code, market authorisation holder and the medicinal product code. It is expected that existing local identifiers will continue, so the MPID for a product approved in the US would have a code of US + the market authorisation holder s DUNS number + the product s National Drug Code (NDC) number. Other jurisdictions have their own IDs that will be repurposed for the MPID including the RVG in the Netherlands and the EU Number for European centrally-approved products. New numbers would be assigned for situations such as changes to the strain used in each season s flu vaccine, for a change to over-the-counter drug sales, in addition to any physical changes to the drug or its packaging. The rest of the identifiers will be prefixed with the MPID, then append a package code, and for batch IDs, a specific batch identifier. The overall data structure is indicated in Figure 1. This shows the relationship between the Medicinal Product itself, the names it has, the versions (this and any previous), manufacturing information, clinical particulars (Indications, Contra-indications and Adverse Events), pharmaceutical products, packaging, and market authorisations for the product and the packaged product. The detailed structure can be found in Appendix B-2. c It s unknown why ISO and HL7 chose a completely separate structure for Investigational Medicinal Products, as there are few differences between them except for a few fields required in one but not the other. Note that EMA followed that lead with the EVPRM model also. 13
17 Figure 1 IDMP Data Model Source: ISO Standard 11615:2012Invalid source specified. The following subsections describe each of the boxes in detail, starting with the Medicinal Product itself and moving clockwise from the Medicinal Product Name Medicinal Product The root object of the standard, the Medicinal Product, provides the broadest identification of the product: MPID (IMPID) Combined Pharmaceutical Dose Form IMPID/MPID Cross Reference Sponsor Product Code Regulatory Product Code This is the identifier for the product or investigational product. The standard specifies that the ID should always be provided, but does not specify what should be done on an initial filing, before the ID has been issued. For the IMPID, the number may include a regulator- or sponsor-provided code, depending on the jurisdiction. This is an optional field used only for combined products, such as Powder and solvent for solution for injection. The IMPID Cross Reference is used in non-investigational products, to refer to a previous investigational ID for the product. An Investigational product may have an MPID Cross Reference if being investigated in a different formulation, packaging or indication than the authorized product. This is found only in Investigational products. Either this or the Regulatory Product Code will be specified This is found only in Investigational products. Either this or the Sponsor Product Code will be specified. 14
18 Paediatric Use Indicator This is found only in Investigational products, indicating whether this is a specific paediatric formulation. Additional Monitoring Indicator Special Measures Medicinal Product Classification This is a safety monitoring term used in the EU, such as Black Triangle This is an optional field used to describe any additional steps that are still required as part of approval, such as Requirement to conduct post-authorization studies. This is not found in Investigational Products One or more classification terms may be provided, listing both a code system and value, such as ATC (World Health Organization s Anatomical Therapeutic Chemical system) DEA Schedule, etc. It is expected that ATC code will be required. The Medicinal Product should not provide much difficulty to assemble. Except for the chicken-andegg problem of getting the initial MPID, this all seems clear. The implementation guide is likely to specify a system similar to XEVMPD, where a local key is provided and flagged as such, until the official number is issued, but the standard does not indicate any means of linking to an earlier local value the way XEVPRM does. This will likely be specified in the ICH implementation guide. Note that many portions of the Medicinal Product structure have a near-duplicate structure for Investigational Medicinal Products. In implementation in a database, it may be more effective to have a single structure that can accommodate both the Investigational and Authorized Medicinal Products, with record-level validation to specify which fields are valid for Investigational versus Authorized products Medicinal Product Name The Medicinal Product Name object permits multiple names to be listed for the product. There must be at least one. Each name may be associated with one or more countries and languages. Name Code Invented Name Part Scientific Name Part Strength Part Pharmaceutical Dose Form Part Formulation Part Intended Use Part Target Population Part Container or Pack Part Device Part This is the full name of the product as it is labeled. This may include a number of components, as described below. The rest of the terms are optional Parts of the whole approved name, used to assist in positively identifying variations on a product. Examples are given below. For an investigational product, a code may be present instead of a name. This is only found in Investigational Products if the product is only referred to as a code instead of a name. The brand or trade name. Typically either this or the scientific name will always exist The generic name, typically the INN. Example: Extra-Strength Example: Easy-Swallow Gelcaps Example: Sugar-Free Example: Arthritis Pain Formula Example: Children (as in Cough Syrup for Children ) Example: Multidose Vial Example: Inhalatron for an inhaler 15
19 Trademark or Company The company name if it appears in the labeled name Name Time / Period Part Example: (as in Myvaccine Flu season Flavour Part Example: Cherry Country / Language Includes the ISO codes for country, sub-country jurisdictions, and language, for example Canada / Quebec / French. Again, this should not be a difficult set of information to manage. EVMPD uses a similar, though less extensive structure Version One or more version sub-objects can be specified that list the date of changes to the IDMP message and one or more regulated documents associated with that version. Jurisdictions may use this to provide the approval letter, Summary of Product Characteristics, etc. A key factor is that a new version must not be a change that would cause the creation of a new Medicinal Product, e.g. the marketing authorization, legal status of supply, name, dose form, ingredients, strength, device provided and indications. Version Date Version Identifier Regulated Document Document Type Document Identifier Regulated Document Document Effective Date Date at which the change occurred A text identifier Associated documents, such as SmPC, Package Leaflet, Approval Letter, Content of Labeling, etc. The information provided includes the type, an identifier for the document, the document itself as an attachment, and the time period when the document became effective. It will be interesting to see how much Version data must be provided for a product which has been on the market for some time, or if the regulatory authorities will only require the current version with the first IDMP submission. Another question will be whether documents need to be provided with each update to the IDMP message, or if they can be sent and registered once and kept on file. The XEVMPD solves this by having the documents be a separate category of objects with their own identifiers, and the product parts of the message only refer to the identifier of the document Manufacturer The manufacturer information corresponds relatively closely to the US Establishment Registration, specifying locations, the operations they perform, and how those establishments were authorized for those operations. This information is optional for Investigational products. 16
20 Manufacturer / Establishment Identifier Name Address Confidentiality Indicator Contact Person Name Telecom Role Confidentiality Indicator Other Locations Location Address Location Role Identifier Manufacturing Operation Operation Type Manufacturing Authorisation Reference Number Effective Date Confidentiality Indicator Medicines Regulatory Agency This includes an identifier (which may be an international ID such as DUNS), name, address, confidentiality, contact names and telecommunications codes ( , phone), and other addresses and their roles (e.g. Batch Release, Qualified Person for Pharmacovigilance [QPPV]). One or more operations at the particular establishment. Operation Type may be items such as Batch Release, Re- Packaging, Re-Labelling, Manufacture, Testing. The Authorisation Reference Number, Date and Agency reflect the authorisation to perform the operation. This information should provide little stress to drug sponsors: It s essentially similar to what is provided for the US Drug Listing / Establishment Registration, although this information is not required for XEVMPD Marketing or Clinical Trial Authorisation The Marketing Authorisation is a more complex structure than the items above, containing subobjects for periodic reporting, marketing status, and marketing authorisation procedures and applications. For Investigational Products, this is a clinical authorisation with slightly different information. Marketing Authorisation Number Country Legal Status of Supply Authorisation Status Authorisation Status Date Validity Period Marketing Authorisation Holder The ID number of the authorisation, which becomes part of the MPID. This may be a licensing number if there is no authorisation number (e.g. a grandfathered product) One or more countries where the authorisation applies. This indicates the type of marketability, e.g. prescription or over-the-counter. Only for authorized products. Status of the product, e.g. Active/Valid, Expired, Renewed, Not Renewed, Withdrawn. Only for authorized products. The date at which the status changed Start and end date of the authorisation. This is the information about the organization that is marketing the product, or in some cases the distributor. This is the same information provided for the Manufacturer/Establishment above. 17
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Disclaimer
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Vada Perkins, CAPT, USPHS US Food and Drug Administration/ Center for Biologics Evaluation and Research 11 October
More informationA Stitch in Time. Understanding and Preparing for the IDMP from a Strategic Level REPORT
A Stitch in Time Understanding and Preparing for the IDMP from a Strategic Level REPORT Outsourcing and Consulting Services for Life Sciences Table of Contents Regulatory Deadline: Driven by EU Legislation...2
More informationThe Main Challenges around IDMP 1 and Ways to Solve Them. Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany
The Main Challenges around IDMP 1 and Ways to Solve Them Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany Abstract: As of 1 July 2016, pharmaceutical companies which develop and
More informationData submission of authorised medicines in the European Union
23 February 2015 EMA/471367/2014, Rev. 1 1 Business Data and Support Department Data submission of authorised medicines in the European Union Outlines on Article 57(2) of Regulation (EC) No 726/2004 1
More informationGuidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
More informationImplementation strategy for ISO IDMP in EU
Implementation strategy for ISO IDMP in EU Paolo Alcini Head of Data Standardisation and Analytics Business Data & Analytics Information Management EMA An agency of the European Union The EU ISO IDMP Task
More informationextended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual
extended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool Version 5.2 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20
More informationThe EMA current activities towards ISO IDMP implementation
The EMA current activities towards ISO IDMP implementation An overview Ginas meeting 11 June 2014 Presented by: Ilaria Del Seppia, B-BD-DCM EMA An agency of the European Union Outlines EMA Vision: Objectives
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationVeterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
More informationContent of Labeling/Product Data Elements SPL Technical Errors Training ebook
Content of Labeling/Product Data Elements SPL Technical s Training ebook Interpretations & s for Technical s in Content of Labeling/Product Data Elements SPL Documents Submitted to FDA Version 1.0 Purpose:
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationEudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationWelcome to the WHO Drug Dictionary Enhanced
Welcome to the WHO Drug Dictionary Enhanced This document is a guide to the general features of the WHO Drug Dictionary Enhanced. You will get information about the structure and content of the dictionary
More informationPL 17871/0208 UKPAR TABLE OF CONTENTS
Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient
More informationGuide to The Notification System for Exempt Medicinal Products
Guide to The Notification System for Exempt Medicinal Products AUT-G0090-1 10 JULY 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
More informationPharmacy Technician Training Program. Minimum Competencies
1. Pharmacy Practice Pharmacy Technician Training Program Minimum Competencies 1.1 The candidate shall be familiar with the mission of pharmacy and the various permitted pharmacy practice sites. The candidate
More informationUnedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010
GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version
More informationReconstitution of Solutions
Chapter 12 Reconstitution of Solutions Reconstitution Process of mixing and diluting solutions Some medications supplied in powder form and must be mixed with liquid before administration Parts of Solutions
More informationDonepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
More informationGuidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationIdentification of Medicinal Products (IDMP) What is necessary in order to be compliant in 2016 and beyond?
Identification of Medicinal Products (IDMP) What is necessary in order to be compliant in 2016 and beyond? February 2015 Audit. Tax. Consulting. Corporate Finance. New ISO standards have been developed
More informationRegulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Inspections London, 19 May 2005 CPMP/QWP/4359/03 EMEA/CVMP/205/04 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
More informationEU Clinical Trials Register
EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory
More informationNEUROTONE THR 00904/0005 UKPAR
NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet
More informationIDMP: An opportunity for information integration across the pharmaceutical value chain
21 IDMP: An opportunity for information integration across the pharmaceutical value chain Author V. Bala Balasubramanian, President & CEO, Cabeus Inc, US. Keywords Identification of medicinal products
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationProfessional Standards and Guidance for the Sale and Supply of Medicines
Professional Standards and Guidance for the Sale and Supply of Medicines About this document The Code of Ethics sets out seven principles of ethical practice that you must follow as a pharmacist or pharmacy
More informationHybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012
More informationMemantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited
More informationEuropean Medicines Agency (EMA) Master Data Management Roadmap Substance, Product, Organisation and Referential data
23 April 2015 EMA/730453/2014 Information Management Division European Medicines Agency (EMA) Master Data Management Roadmap Substance, Product, Organisation and Referential data 30 Churchill Place Canary
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationTESTIMONIAL: Congratulations! Our company s EID Incoming Inspection of AMRESCO-provided products
custom solutions With markets changing so rapidly, AMRESCO is on the front line bringing new technologies and processes so we can deliver solutions that solve our customers problems. TESTIMONIAL: Congratulations!
More informationANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS
ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationOverview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP)
Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP) Summary This document examines the key aspects of the CLP
More informationIMPORTANCE OF THE ENFORCEMENT OF THE LAW AND EU DIRECTIVES CONCERNING TRANSLATION OF PHARMACEUTICALS LEAFLETS
IMPORTANCE OF THE ENFORCEMENT OF THE LAW AND EU DIRECTIVES CONCERNING TRANSLATION OF PHARMACEUTICALS LEAFLETS Qendro Gentiana Planetary University, Faculty of Medical Sciences, Department of Pharmacy,
More informationEDUCATOR S LESSON PLAN
EDUCATOR S LESSON PLAN Pharmacy Technician Training Program Student Version Orientation Orientation introduces the student to basic terms and definitions. An introduction to the Pharmacy Technician Certification
More informationGuideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations
More informationPublic Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
More informationSTREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES
STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE
More informationTG 47-01. TRANSITIONAL GUIDELINES FOR ISO/IEC 17021-1:2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES
TRANSITIONAL GUIDELINES FOR ISO/IEC 17021-1:2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES Approved By: Senior Manager: Mpho Phaloane Created By: Field Manager: John Ndalamo Date of Approval:
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationRILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS
RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More information2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
More informationOmeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
More informationCoventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
More informationBilling with National Drug Codes (NDCs) Frequently Asked Questions
Billing with National Drug Codes (NDCs) Frequently Asked Questions NDC Overview Converting HCPCS/CPT Units to NDC Units Submitting NDCs on Professional/Ancillary Claims Reimbursement Details For More Information
More informationHUMAN MEDICINES. Generic medicines. Our advice
HUMAN MEDICINES Generic medicines Our advice hpra.ie Our advice on Generic medicines This leaflet answers some of the most common questions about generic medicines. In particular, it includes information
More informationAnnex 7 Guidelines on pre-approval inspections
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the
More informationLacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken
More informationSummary Public Assessment Report. Generics
Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin
More informationMACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
More informationICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content
More informationCombination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
More informationEvaluating Current Practices in Shelf Life Estimation
Definition of Evaluating Current Practices in Estimation PQRI Stability Working Group Pat Forenzo Novartis James Schwenke Applied Research Consultants, LLC From ICH Q1E An appropriate approach to retest
More informationSummary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,
Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January
More informationGeneral Principles for the Safety Assessment of Excipients
General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how
More informationAciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
More informationLEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)
LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More information1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
More informationWelcome to the WHO Herbal Dictionary
Welcome to the WHO Herbal Dictionary This document is a guide to the general features of the WHO Herbal Dictionary. It provides you with information about the structure and content of the dictionary as
More informationCOMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
More informationUrostemol Men capsules THR 02855/0240
Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationPublic Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921
Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationSTABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW
More informationWissenschaftliche Prüfungsarbeit. zur Erlangung des Titels. Master of Drug Regulatory Affairs
TITLE PAGE The new Clinical Trial Regulation and corresponding new EU portal and database: an opportunity to enhance standardisation and interoperability in regulatory systems Wissenschaftliche Prüfungsarbeit
More informationEU Individual Case Safety Report (ICSR) 1 Implementation Guide
4 December 2014 EMA/51938/2013 EU Individual Case Safety Report (ICSR) 1 Implementation Guide Start of Public Consultation 30 April 2014 End of Public Consultation 30 June 2014 Final draft agreed by Project
More informationQueensland recordkeeping metadata standard and guideline
Queensland recordkeeping metadata standard and guideline June 2012 Version 1.1 Queensland State Archives Department of Science, Information Technology, Innovation and the Arts Document details Security
More informationAuthorisation and Restriction Newsletter
Authorisation and Restriction Newsletter August 2010, N 1 The information contained in this document is intended for guidance only and whilst the information is provided in utmost good faith and has been
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationWhat is the correct title of this publication? What is the current status of understanding and implementation?
GMP Rules and Guidelines in 2013 for Computer System Validation / Computerises Systems / Electronic Records and Signatures/ IT Infrastructure and Application Compliance: What is the correct title of this
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationSession 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
More informationAmerican Association of Tissue Banks: Impact on FDA s UDI Final Rule
American Association of Tissue Banks: Impact on FDA s UDI Final Rule TOPIC INITIAL FDA PROPOSAL AATB COMMENT FDA FINAL RULE (INCLUDING COMMENTS) ISBT 128 FDA noted the presence of GS1 [which uses the Global
More informationPhynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR
Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Summary of Product Characteristics Page
More informationChemicals Regulation: A comparison of US and European Approaches. James Searles
Chemicals Regulation: A comparison of US and European Approaches James Searles April 11, 2011 www.steptoe.com April 11, 2011 TSCA vs.. REACH - OVERVIEW Both TSCA and REACH aim at gathering scientific information
More information